Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial

医学 吡非尼酮 西地那非 肺动脉高压 特发性肺纤维化 安慰剂 双盲 肺纤维化 内科学 纤维化 病理 替代医学
作者
Jürgen Behr,Steven D. Nathan,Wim Wuyts,Nesrin Moğulkoç,Demosthenes Bouros,Katerina M. Antoniou,Julien Guiot,Mordechai R. Kramer,Klaus-Uwe Kirchgaessler,Monica Bengus,Frank Gilberg,Andras Perjesi,Sergio Harari,Athol U. Wells
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:9 (1): 85-95 被引量:100
标识
DOI:10.1016/s2213-2600(20)30356-8
摘要

Summary

Background

The benefit of sildenafil in patients with advanced idiopathic pulmonary fibrosis (IPF) at risk of poor outcomes from pulmonary hypertension, whether already present or likely to develop, is uncertain. We aimed to assess the efficacy and safety of sildenafil added to pirfenidone versus placebo added to pirfenidone for 52 weeks in patients with advanced IPF and at risk of group 3 pulmonary hypertension.

Methods

We did a multicentre, international, double-blind, randomised, placebo-controlled, phase 2b study at 56 university clinics, research hospitals, and tertiary sites in Canada, Europe (Belgium, Czech Republic, Germany, Greece, Hungary, Italy, the Netherlands, Spain, and Turkey), Israel, and Africa (Egypt and South Africa). Eligible patients (aged 40–80 years) had advanced IPF (carbon monoxide diffusing capacity ≤40% predicted at screening), and were at risk of group 3 pulmonary hypertension (mean pulmonary artery pressure of ≥20 mm Hg with pulmonary artery wedge pressure of ≤15 mm Hg on previous right-heart catheterisation, or intermediate or high probability of group 3 pulmonary hypertension on echocardiography as defined by the 2015 European Society of Cardiology and European Respiratory Society guidelines). Patients were randomly assigned 1:1 to oral sildenafil tablets (20 mg three times daily) or placebo, both in addition to oral pirfenidone capsules (801 mg three times daily), using a validated interactive voice-based or web-based response system with permuted block randomisation, stratified by previous right-heart catheterisation (yes or no) and forced expiratory volume in 1 s to forced vital capacity ratio (<0·8 or ≥0·8). The composite primary endpoint was disease progression, defined as either a relevant decline in 6-min walk distance, respiratory-related admission to hospital, or all-cause mortality, after 52 weeks and was assessed in the intention-to-treat population; safety was assessed in all patients who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov, NCT02951429, and is no longer recruiting. The 11-month safety follow-up is ongoing.

Findings

Between Jan 13, 2017, and Aug 30, 2018, 247 patients were screened for eligibility, 177 of whom were randomly assigned to a treatment group (n=88 sildenafil; n=89 placebo) and were assessed for the primary outcome. There was no difference in the proportion of patients with disease progression over 52 weeks between the sildenafil (64 [73%] of 88 patients) and placebo groups (62 [70%] of 89 patients; between-group difference 3·06% [95% CI −11·30 to 17·97]; p=0·65). Serious treatment-emergent adverse events were reported in 54 (61%) patients in the sildenafil group and 55 (62%) patients in the placebo group. Treatment-emergent adverse events leading to mortality occurred in 22 (25%) patients in the sildenafil group and 26 (29%) in the placebo group.

Interpretation

Addition of sildenafil to pirfenidone did not provide a treatment benefit versus pirfenidone plus placebo up to 52 weeks in patients with advanced IPF and risk of pulmonary hypertension. No new safety signals were identified with either treatment. Although the absence of a beneficial treatment effect suggests that sildenafil is not an appropriate treatment in the overall population, further research is required to establish if specific subgroups of patients with IPF might benefit from sildenafil.

Funding

F Hoffmann-La Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
追寻源智发布了新的文献求助10
刚刚
刚刚
yuanyuan发布了新的文献求助10
1秒前
NexusExplorer应助钟ZJ采纳,获得10
1秒前
发文章发布了新的文献求助10
2秒前
赘婿应助学术奴才采纳,获得10
2秒前
土亢土亢土完成签到,获得积分0
3秒前
3秒前
yoneyamai发布了新的文献求助10
5秒前
大个应助慕容雅柏采纳,获得10
5秒前
幸福的雪枫完成签到,获得积分10
6秒前
外向的忆霜完成签到,获得积分10
6秒前
fighting发布了新的文献求助10
6秒前
smm完成签到 ,获得积分10
6秒前
Tao完成签到,获得积分10
7秒前
缓慢的开山完成签到 ,获得积分10
8秒前
笑点低的咖啡完成签到,获得积分10
8秒前
8秒前
细腻亦巧发布了新的文献求助10
8秒前
zm完成签到,获得积分10
9秒前
10秒前
10秒前
不懂科研的小徐完成签到,获得积分10
11秒前
12秒前
大模型应助twob采纳,获得10
12秒前
12秒前
你的女孩TT完成签到,获得积分10
12秒前
12秒前
13秒前
昏睡的蟠桃应助合适夏天采纳,获得200
14秒前
yuanyuan完成签到,获得积分10
15秒前
16秒前
16秒前
在水一方应助积极的邪欢采纳,获得10
16秒前
慕容雅柏发布了新的文献求助10
16秒前
lasdklas发布了新的文献求助10
17秒前
天天完成签到 ,获得积分10
17秒前
vc小星完成签到,获得积分10
18秒前
icerain发布了新的文献求助10
18秒前
18秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
Interpretation of Mass Spectra, Fourth Edition 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3951800
求助须知:如何正确求助?哪些是违规求助? 3497233
关于积分的说明 11086336
捐赠科研通 3227767
什么是DOI,文献DOI怎么找? 1784520
邀请新用户注册赠送积分活动 868692
科研通“疑难数据库(出版商)”最低求助积分说明 801163